QR-010

July 21, 2016July 21, 2016

FDA Grants Fast Track Status to Cystic Fibrosis Therapy QR-010 by ProQR

Cystic Fibrosis, News

ProQR Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its molecule QR-010 for the treatment of cystic fibrosis (CF) patients who have the deltaF508 mutation in ... Read more

June 29, 2016June 29, 2016

Phase 1 Trial Data on RNA-based Therapy for CF to Be Presented at NACFC 2016

Cystic Fibrosis, News

ProQR Therapeutics recently announced that new data from an ongoing proof-of-concept clinical study, called PQ-010-002, evaluating the effect of an RNA-based therapy (QR-010) on cystic fibrosis patients, will be presented at the North American Cystic Fibrosis Conference ... Read more

September 17, 2015November 5, 2015

ProQR Begins Enrollment in Clinical Trial Testing New Cystic Fibrosis Therapy

Cystic Fibrosis, News

ProQR therapeutics recently announced that they have begun enrolling patients for their open-label, exploratory trial PQ-010-002, which will evaluate the effect of their novel investigational therapeutic formulation QR-010 in ∆F508 homozygous ... Read more